321 related articles for article (PubMed ID: 28260071)
1. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
[TBL] [Abstract][Full Text] [Related]
2. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
[TBL] [Abstract][Full Text] [Related]
3. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
4. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
5. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival.
Salian-Mehta S; Xu M; Wierman ME
Mol Cell Endocrinol; 2013 Jul; 374(1-2):92-100. PubMed ID: 23648337
[TBL] [Abstract][Full Text] [Related]
6. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
7. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
8. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389
[TBL] [Abstract][Full Text] [Related]
9. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
10. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
[TBL] [Abstract][Full Text] [Related]
13. Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells.
Kim KC; Baek SH; Lee C
Int J Oncol; 2015 Dec; 47(6):2296-303. PubMed ID: 26498137
[TBL] [Abstract][Full Text] [Related]
14. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
15. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
16. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
17. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
Shi W; Song J; Wang W; Zhang Y; Zheng S
Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
[TBL] [Abstract][Full Text] [Related]
18. FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma.
Cooke M; Kreider-Letterman G; Baker MJ; Zhang S; Sullivan NT; Eruslanov E; Abba MC; Goicoechea SM; García-Mata R; Kazanietz MG
Cell Rep; 2021 Nov; 37(5):109905. PubMed ID: 34731623
[TBL] [Abstract][Full Text] [Related]
19. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
20. AXL and acquired resistance to EGFR inhibitors.
Postel-Vinay S; Ashworth A
Nat Genet; 2012 Jul; 44(8):835-6. PubMed ID: 22836088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
